Here, tumor PD-L1 expression quantification could be a helpful tool, assuming that patients showing PD-L1 positivity are more likely to benefit from ICB, and patients with PD-L1-negative tumors may be more likely to benefit from targeted therapy. The gene discussed is CD274; the disease is neoplasm.